Abstract
Aims: The FINDRISC questionnaire is a screening tool to estimate the risks for type 2 diabetes
as well as asymptomatic type 2 diabetes. We aimed to evaluate its performance to predict
diabetes in a German population and to compare its predictive and detective ability
in the same population.
Methods: A total of 552 subjects with increased risk of type 2 diabetes were investigated.
All individuals completed the FINDRISC questionnaires and underwent an oral glucose
tolerance test (OGTT). All individuals were followed for 3 years and underwent an
OGTT again. The performance of the opportunistic screening was assessed with the area
under the receiver operating characteristics curve (AUC). An intervention program
was carried out for all diabetic and IFG/IGT patients at baseline.
Results: For identification, the asymptomatic type 2 DM was named Condition 1; prediction
of type 2 DM risk in the follow-up survey as Condition 2; and diabetes risk predicting
in a hypothetical case of survey without intervention program as Condition 3. The
ROC-AUC in the three condition were AUCFINDRISC1 =0.745, AUCFINDRISC2 =0.789, and AUCFINDRISC3 =0.775, respectively. A significant association between FINDRISC and evolution of
disease was found, but the variation of plasma glucose during the three years follow-up
was not associated with FINDRISC. People in the intervention group with an improvement
of glucose tolerance had a smaller FINDRISC score than persons with an unchanged or
progressive condition of disease.
Conclusion: FINDRISC was validated in our study as a simple tool with high performance to predict
diabetes risk and less efficient to identify asymptomatic type 2 diabetes. People
with lower FINDRISC score will benefit easier from preventive intervention.
Key words
Diabetes risk score - predicting of diabetes risk
References
1
Drewes T. et al .
Estrogen-inducible derivatives of hepatocyte nuclear factor-4, hepatocyte nuclear
factor-3 and liver factor B1 are differently affected by pure and partial antiestrogens.
Eur J Biochem.
1994;
225
441-448
2
Linnemann B. et al .
C-reactive protein is a strong independent predictor of death in type 2 diabetes:
association with multiple facets of the metabolic syndrome.
Exp Clin Endocrinol Diabetes.
2006;
114
((3))
127-134
3
Valensi P. et al .
Pre-diabetes essential action: a European perspective.
Diabetes Metab.
2005;
31
606-620
4
Knowler WC. et al .
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med.
2002;
346
393-403
5
Pan XR. et al .
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.
The Da Qing IGT and Diabetes Study.
Diabetes Care.
1997;
20
537-544
6
Tuomilehto J. et al .
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with
impaired glucose tolerance.
N Engl J Med.
2001;
344
1343-1350
7
Chiasson JL. et al .
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
8
Torgerson JS. et al .
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized
study of orlistat as an adjunct to lifestyle changes for the prevention of type 2
diabetes in obese patients.
Diabetes Care.
2004;
27
155-161
9
Wenying Y. et al .
The preventive effect of acarbose and metformin on the IGT population from becoming
diabetes mellitus: a 3-year multicenter prospective study.
Chin J Endocrinol Metab.
2001;
17
131-136
10
Schwarz PE. et al .
Development of a diabetes prevention management program for clinical practice.
Public Health Rep.
2007;
122
258-263
11
Schwarz PE. et al .
Diabetes prevention - from physiology to implementation.
Horm Metab Res.
2006;
38
460-464
12
Simons WR. et al .
Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes
mellitus benefit glycaemic control and diabetes-related complications? A German population-based
study.
Exp Clin Endocrinol Diabetes.
2006;
114
((9))
520-526
13
Schwarz PE, Bornstein SR.
Pre-diabetes and metabolic syndrome in Germans.
Horm Metab Res.
2006;
38
359
14
Schwarz PE, Bornstein SR, Hanefeld M.
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.
Diabetes Res Clin Pract.
2007;
77
148-150
15
Schwarz PE.
Congress report from the American diabetes association 66th annual scientific sessions
in Washington, USA.
Exp Clin Endocrinol Diabetes.
2006;
114
((10))
605-610
16
Lindstrom J, Tuomilehto J.
The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk.
Diabetes Care.
2003;
26
725-731
17
Saaristo T. et al .
Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify
undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome.
Diab Vasc Dis Res.
2005;
2
67-72
18
Olckers A. et al .
Protective effect against type 2 diabetes mellitus identified within the ACDC gene
in a black South African diabetic cohort.
Metabolism.
2007;
56
587-592
19
Schwarz PE. et al .
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic
variation in the ADIPOQ gene promoter.
Diabetes Care.
2006;
29
1645-1650
20
Thamer C. et al .
Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors
for the change of postprandial glucose in non-diabetic subjects at risk for type 2
diabetes.
Horm Metab Res.
2006;
38
178-182
21
Gouni-Berthold I. et al .
The K121Q polymorphism of the plasma cell glycoprotein-1 gene is not associated with
diabetes mellitus type 2 in German Caucasians.
Horm Metab Res.
2006;
38
524-529
22
Fisher E. et al .
Preliminary evidence of FABP2 A54 T polymorphism associated with reduced risk of type
2 diabetes and obesity in women from a German cohort.
Horm Metab Res.
2006;
38
341-345
23
Haslbeck KM. et al .
The AGE/RANGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy
in impaired glucose tolerance (IGT).
Exp Clin Endocrinol Diabetes.
2005;
113
((5))
288-291
24
Uhlmann K. et al .
Genetics of diabetic retinopathy.
Exp Clin Endocrinol Diabetes.
2006;
114
((6))
275-294
25
Schwarz P.
High risk strategy in diabetes prevention - pro.
Dtsch Med Wochenschr.
2005;
130
1103
26
Schwarz PE. et al .
Haplotypes in the promoter region of the ADIPOQ gene are associated with increased
diabetes risk in a German caucasian population.
Horm Metab Res.
2006;
38
447-451
27
Parhofer KG.
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
Exp Clin Diabetes.
2005;
113
((8))
414-417
28 World Health Organization .Definition, diagnosis and classification of diabetes
mellitus and its complications. Report of a WHO Consultation 1999
29
Schuppenies A. et al .
FINDRISK: Finde das Risiko! - Entwicklung eines Fragebogens zur Einschätzung des Diabetesrisikos.
Ernährungs-Umschau.
2006;
53
386-389
30
Kubaszek A. et al .
Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the
conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes
Prevention Study.
Diabetes.
2003;
52
1872-1876
31
Zweig MH, Campbell G.
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical
medicine.
Clin Chem.
1993;
39
561-577
32
Hanley JA, MacNeil BJ.
A method of comparing the areas under receiver operating characteristic curves derived
from the same cases.
Radiology.
1983;
148
839-843
33
Wenying Y. et al .
The preventive effect of acarbose and metformin on the progression to diabetes mellitus
in the IGT population: a 3-year multicenter prospective study.
Chin J Endocrinol Metab.
2001;
17
131-136
34
Schwarz PE. et al .
Prevention of type 2 diabetes: what challenges do we have to address?.
J Pub Health.
2005;
13
296-303
35
Schwarz PE. et al .
Prevention of diabetes mellitus: The future of German diabetology.
Hamostaseologie.
2007;
27
13-21
36
Franciosi M. et al .
Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes
and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term
Outcomes Observational) study.
Diabetes care.
2005;
28
1187-1194
37
Stern MP, Williams K, Haffner SM.
Identification of persons at high risk for type 2 diabetes mellitus: do we need the
oral glucose tolerance test?.
Ann Int Med.
2002;
136
575-581
38
Kanaya AM. et al .
Predicting the development of diabetes in older adults: the derivation and validation
of a prediction rule.
Diabetes Care.
2005;
28
404-408
39
Schulze MB. et al .
An accurate risk score based on anthropometric, dietary, and lifestyle factors to
predict the development of type 2 diabetes.
Diabetes Care.
2007;
30
510-515
40
Schwarz PEH. et al .
An accurate risk score based on anthropometric, dietary, and lifestyle factors prediet
the development of type 2 diabetes, response to schulze et al.
Diabetes care.
2007;
30
((8))
e87
41
Hanefeld M. et al .
The metabolic syndrome - a postprandial disease?.
Horm Metab Res.
2006;
38
435-436
Correspondence
Dr. med. P. E.H. Schwarz
Department of Medicine III
Carl Gustav Carus Medical School
Dresden University of Technology
Fetscherstrasse 74
01307 Dresden
Germany
Phone: +49/351/458 27 15
Fax: +49/351/458 73 19
Email: peter.schwarz@uniklinikum-dresden.de